ArticleJournal of neurology2026
Superior oblique myokymia: diagnostic criteria and long-term outcome.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSuperior oblique myokymia (SOM) is a rare disorder characterized by brief episodes of high-frequency, low-amplitude monocular nystagmus frequently caused by vascular contact with the trochlear nerve. Comprehensive analyses of SOM symptomatology and long-term progression are limited. No diagnostic criteria are available.
methodsAdult patients who were diagnosed with SOM between 2008 and 2024 were asked to complete a detailed questionnaire on disease symptomatology, time course, and medication. The impact of the disease on patient-reported functioning was assessed using a Likert scale. In addition, medical records were screened in all patients.
resultsA total of 35 patients with SOM were identified (21 females; mean age at symptom onset 42.8 ± 15.0 years). 30 patients experienced visuo-perceptual symptoms (i.e., diplopia or oscillopsia, 85.7%), 22 patients ocular motor symptoms (i.e., noticeable "eye-twitching", 62.9%), and 15 patients dizziness or gait instability (42.9%). Of 22 patients analyzed for their long-term therapeutic outcome, 13 described symptom improvement with pharmacotherapy, and six without pharmacotherapy. Patients experienced a moderate to high impact of the disease on their daily private and professional lives. Based on these findings, specific diagnostic criteria for SOM were proposed.
conclusionsSOM can substantially impair patients' quality of life and daily functioning. The long-term course appears favorable, with most patients experiencing either complete remission or significant symptom reduction over time. Pharmaceutical treatment proved effective in nearly 90% of patients, and spontaneous remission was also observed. Further research should focus on larger patient cohorts defined by clear diagnostic criteria to enhance understanding of SOM's natural history and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.